Whole-body positron emission tomography in clinical oncology: Comparison between attenuation-corrected and uncorrected images

European Journal of Nuclear Medicine

Volumn 24, Issue 9, 1997, Pages 1091-1098

  Bengel, Frank M ^a,b   Ziegler, Sibylle I ^a   Avril, Norbert ^a   Weber, Wolfgang ^a   Laubenbacher, Christian ^a   Schwaiger, Markus ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Attenuation correction; Fluorine 18 fluorodeoxyglucose; Whole body positron emission tomography

Indexed keywords

FLUORINE 18; FLUORODEOXYGLUCOSE; TRACER;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; FEMALE; HUMAN; IMAGE ENHANCEMENT; MALE; METASTASIS; ONCOLOGY; PHANTOM; RADIATION ATTENUATION; TUMOR LOCALIZATION; WHOLE BODY TOMOGRAPHY;

FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; NEOPLASMS; PHANTOMS, IMAGING; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED;

ELECTRONS; FLUORINE; IMAGE SEGMENTATION; PHANTOMS; POSITRONS;

ATTENUATION CORRECTION; CLINICAL ONCOLOGY; CORRECTED IMAGE; FLUORINE-18; FLUORINE-18 FLUORODEOXYGLUCOSE; FLUORODEOXYGLUCOSE; HIGH CONTRAST; PHANTOMS; WHOLE-BODY; WHOLE-BODY POSITRON EMISSION TOMOGRAPHY;

POSITRON EMISSION TOMOGRAPHY;

EID: 0030865170     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050126     Document Type: Article

References (27)

1. Adler LP, Bloom AD. Positron emission tomography of thyroid masses. Thyroid 1993; 3: 195-200.
2. Avril N, Dose J, Janicke F, et al. Metabolic characterization of breast tumours with positron emission tomography using F-18 fluorodeoxyglucose. J Clin Oncol 1996; 14: 1848-1857.
3. Casey MJ, Gupta NC, Muths CK. Experience with positron emission tomography (PET) scans in patients with ovarian cancer. Gynecol Oncol 1994; 53: 331-338.
4. Falk PM, Gupta NC, Thorson AG, et al. Positron emission tomography for preoperative staging of colorectal carcinoma. Dis Colon Rectum 1994; 37: 153-6.
5. Gritters LS, Francis IR, Zasadny KR, Wahl RL. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma. J Nucl Med 1993; 34: 1420-1427.
6. Laubenbacher C, Saumweber D, Wagner MC, et al. Comparison of fluorine-18-fluorodeoxyglucose PET, MRI and endoscopy for staging head and neck squamous-cell carcinomas. J Nucl Med 1995; 36: 1747-57.
7. Stollfuss JC, Glatting G, Friess H, Kocher F, Berger HG, Reske SN. 2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation. Radiology 1995; 195: 339-344.
8. Wahl RL, Quint LE, Greenough RL, Meyer CR, White RI, Orringer MB. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. Radiology 1994; 191: 371-377.
9. 18F]fluoro-2-deoxy-D-glucose. J Comput Assist Tomogr 1993; 17: 582-589.
10. Dahlbom M, Hoffman EJ, Hoh CK, et al. Whole-body positron emission tomography: Part I. Methods and performance characteristics. J Nucl Med 1992; 33: 1191-1199.
11. 18F]fluorodeoxyglucose in recurrent colorectal cancer. Br J Surg 1994; 81: 1666-1670.
12. Lewis P, Griffin S, Marsden P, et al. Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer. Lancet 1994; 344: 1265-1266.
13. Rege SD, Hoh CK, Glaspy JA, et al. Imaging of pulmonary mass lesions with whole-body positron emission tomography and fluorodeoxyglucose. Cancer 1993; 72: 82-90.
14. Karlan BY, Hawkins R, Hoh C, et al. Whole-body positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma. Gynecol Oncol 1993; 51: 175-181.
15. Steinert HC, HuchBoni R, Buck A, et al. Malignant melanoma: staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1995; 195: 705-709.
16. Engel H, Steinert H, Buck A, Berthold T, HuchBoni RA, von Schulthess GK. Whole-body PET: physiological and artifactual fluorodeoxyglucose accumulations. J Nucl Med 1996; 37: 441-446.
17. 18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986; 27: 235-238.
18. Wienhard K, Eriksson L, Grootoonk S, Casey M, Pietrzyk U, Heiss WD. Performance evaluation of the positron scanner ECAT EXACT. J Comput Assist Tomogr 1992; 16: 804-813.
19. Ziegler SI, Schad D, Kuhnel D, Kruschke C, Schwaiger M. Postinjection and simultaneous transmission measurements for clinical PET. Eur J Nucl Med 1995; 22: 788.
20. Zasadny KR, Kison PV, Quint LE, Wahl RE. Quantification of systematic distortion in non-attenuation corrected FDG-PET images in patients with untreated lung cancers. J Nucl Med 1995; 36: 5P.
21. Carson RE, DaubeWitherspoon M, Green MV. A method for postinjection PET transmission measurements with a rotating source. J Nucl Med 1988; 29: 1558-1567.
22. Huang SC, Hoffman EJ, Phelps ME, Kuhl DE. Quantitation in positron emission computed tomography: 2. Effects of inaccurate attenuation correction. J Comput Assist Tomogr 1979; 3: 804-814.
23. Hawkins RA, Hoh C, Glaspy J, et al. The role of positron emission tomography in oncology and other whole-body applications. Semin Nucl Med 1992; 22: 268-284.
24. Keyes JJ. SUV: standard uptake or silly useless value? J Nucl Med 1995; 36: 1836-1839.
25. Xu EZ, Mullani NA, Gould KL, Anderson WL. A segmented attenuation correction for PET. J Nucl Med 1991; 32: 161-165.
26. Meikle SR, Dahlbom M, Cherry SR. Attenuation correction using count-limited transmission data in positron emission tomography. J Nucl Med 1993; 34: 143-150.
27. Meikle SR, Bailey DL, Hooper PK, et al. Simultaneous emission and transmission measurements for attenuation correction in whole-body PET. J Nucl Med 1995; 36: 1680-1688.